Fast and Sensitive HPLC-ESI-MS/MS Method for Etoricoxib Quantification in Human Plasma and Application to Bioequivalence Study

被引:6
作者
Loh, Gabriel Onn Kit [1 ]
Wong, Emily Yii Ling [1 ]
Tan, Yvonne Tze Fung [1 ]
Heng, Siew Chyee [2 ]
Saaid, Mardiana [2 ]
Cheah, Kit Yee [3 ]
Sali, Nurul Diyana Mohd [3 ]
Damenthi, Nair [3 ]
Ng, Sharon Shi Min [3 ]
Ming, Long Chiau [4 ]
Peh, Kok Khiang [5 ]
机构
[1] Bioxis Sdn Bhd, PMT 1241,Jalan Perind Bukit Minyak 8, Simpang Ampat 14100, Malaysia
[2] Univ Sains Malaysia, Sch Chem Sci, Minden 11800, Malaysia
[3] Minist Hlth Malaysia, Ctr Clin Trial, Inst Clin Res, Natl Inst Hlth,Hosp Ampang, Ampang 68000, Malaysia
[4] Univ Brunei Darussalam, PAP Rashidah Saadatul Bolkiah Inst Hlth Sci, BE-1410 Gadong, Brunei
[5] Univ Sains Malaysia, Sch Pharmaceut Sci, Minden 11800, Malaysia
来源
MOLECULES | 2022年 / 27卷 / 17期
关键词
etoricoxib; etoricoxib D4; protein precipitation; high-sample throughput; human plasma; bioequivalence study; SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; PHARMACOKINETICS; QUANTITATION; VALIDATION; ABSORPTION; KETOPROFEN; PROFILE;
D O I
10.3390/molecules27175706
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. The objective of the current study was to develop a sensitive, fast and high-throughput HPLC-ESI-MS/MS method to measure etoricoxib levels in human plasma using a one-step methanol protein precipitation technique. A tandem mass spectrometer equipped with an electrospray ionization (ESI) source operated in a positive mode and multiple reaction monitoring (MRM) were used for data collection. The quantitative MRM transition ions were m/z 359.15 > 279.10 and m/z 363.10 > 282.10 for etoricoxib and IS. The linear range was from 10.00 to 4000.39 ng/mL and the validation parameters were within the acceptance limits of the European Medicine Agency (EMA) and Food and Drug Analysis (FDA) guidelines. The present method was sensitive (10.00 ng/mL with S/N > 40), simple, selective (K prime > 2), and fast (short run time of 2 min), with negligible matrix effect and consistent recovery, suitable for high throughput analysis. The method was used to quantitate etoricoxib plasma concentrations in a bioequivalence study of two 120 mg etoricoxib formulations. Incurred sample reanalysis results further supported that the method was robust and reproducible.
引用
收藏
页数:15
相关论文
共 41 条
  • [1] Pharmacokinetics of etoricoxib in patients with renal impairment
    Agrawal, NGB
    Matthews, CZ
    Mazenko, RS
    Kline, WE
    Woolf, EJ
    Porras, AG
    Geer, LA
    Wong, PH
    Cho, MH
    Cote, J
    Marbury, TC
    Moncrief, JW
    Alcorn, H
    Swan, S
    Sack, MR
    Robson, RA
    Petty, KJ
    Schwartz, JI
    Gottesdiener, KM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (01) : 48 - 58
  • [2] Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man
    Agrawal, NGB
    Porras, AG
    Matthews, CZ
    Rose, MJ
    Woolf, EJ
    Musser, BJ
    Dynder, AL
    Mazina, KE
    Lasseter, KC
    Hunt, TL
    Schwartz, JI
    McCrea, JB
    Gottesdiener, KM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (03) : 268 - 276
  • [3] Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers
    Agrawal, NGB
    Porras, AG
    Matthews, CZ
    Woolf, EJ
    Miller, JL
    Mukhopadhyay, S
    Neu, DC
    Gottesdiener, KM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (10) : 1106 - 1110
  • [4] Stability Study of Etoricoxib a Selective Cyclooxygenase-2 Inhibitor by a New Single and Rapid Reversed Phase HPLC Method
    Alzweiri, Muhammad
    Sallam, Mariam
    Al-Zyoud, Walid
    Aiedeh, Khaled
    [J]. SYMMETRY-BASEL, 2018, 10 (07):
  • [5] [Anonymous], 2018, BIOAN METH VAL GUID
  • [6] [Anonymous], 2015, GUID COND BIOEQ STUD
  • [7] Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation
    Bräutigam, L
    Nefflen, JU
    Geisslinger, G
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 788 (02): : 309 - 315
  • [8] System suitability in bioanalytical LC/MS/MS
    Briscoe, Chad J.
    Stiles, Mark R.
    Hage, David S.
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 44 (02) : 484 - 491
  • [9] BROOKS PM, 1991, NEW ENGL J MED, V324, P1716
  • [10] Statistical Assessment of Biosimilar Products
    Chow, Shein-Chung
    Liu, Jen-pei
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (01) : 10 - 30